Dexamethasone Treatment Options in United Kingdom

A collection of 187 research studies where Dexamethasone is the interventional treatment. These studies are located in the United Kingdom . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.

Home

United Kingdom

All Treatments

Dexamethasone

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

An Investigational Study of Hydrocortisone

NCT01960530

Completed

This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone. Hydrocortisone is used as a replacement treatment for people whose adrenal glands are not producing enough natural cortisol - a condition known as adrenal insufficiency. The study will assess how Infacort® acts once inside the body, by measuring cortisol and other hormone levels in the body, compared to already marketed hydrocortisone tablet a... Read More

Gender:

MALE

Ages:

Between 18 years and 60 years

Trial Updated:

04/05/2022

Locations: Simbec Research Limited, Merthyr Tydfil, Not set

Conditions: Adrenal Insufficiency

Learn More ›

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

NCT04115956

Terminated

This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy. Melflufen will be administered on Day 1 of each 28-day cycle in combination with dexamethasone on days 1 and 2. In both phases, treatment of each individual participant will continue for up to 8 cycles or until any stopping events occur. Approximately 46 participants will be enrolled. The study was intend... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/10/2022

Locations: Boston University Medical Center, Boston, Massachusetts +8 locations

Conditions: AL Amyloidosis

Learn More ›

Optimising Renal Outcome in Myeloma Renal Failure

NCT02424851

Completed

The purpose of this study is to compare the effectiveness of bortezomib versus thalidomide in reducing free light chains in the blood of myeloma patients. In addition participants will receive bendamustine (chemotherapy) and dexamethasone (steroids), which increase the effectiveness of both bortezomib and thalidomide. The trial will also study whether an earlier reduction of free light chains increases the chances of the kidneys recovering.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/26/2022

Locations: Basingstoke & North Hampshire Hospital, Basingstoke, Not set +8 locations

Conditions: Multiple Myeloma, Chronic Kidney Disease

Learn More ›

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

NCT01712789

Completed

The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. The study consists of a Screening phase within 28 days prior to cycle 1 day 1, a Treatment phase and a Follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years. In addition, the collection of... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/10/2021

Locations: Medical University of Graz, Graz, Not set +111 locations

Medical University of Graz, Graz, Not set

Medizinische Universitat Innsbruck, Innsbruck, Not set

Wilhelminenspital Vienna, Vienna, Not set

Medical University of Vienna, Vienna, Not set

AZ St-Jan Brugge Oostende AV, Brugge, Not set

Institut Jules Bordet, Brussels, Not set

VUB Vrije Universiteit Brussel, Brussel, Not set

UZ Gent, Gent, Not set

UZ Leuven, Leuven, Not set

Centre Hospitalier Universitaire de Liege, Liege, Not set

CHU Mont -Godinne, Yvoir, Not set

Aarhus University Hospital, Aarhus, Not set

Odense University Hospital, Odense, Not set

Vejle Hospital, Vejle, Not set

Tartu University Hospital Clinic, Tartu, Not set

Helsingin yliopistollinen keskussairaala, Helsinki, Not set

Turku University Hospital, Turku, Not set

Centre Hospitalier de la cote basque, Bayonne, Not set

Hopital Henri Mondor, Créteil, Not set

Hopital A. Michallon, La Tronche, Not set

CHRU Claude Huriez, Lille, Not set

Institut Paoli Calmette Hematologie, Marseille cedex, Not set

CHU Hotel Dieu, Nantes, Not set

Hopital Saint Antoine, Paris, Not set

Service Hemato-Immunologie Hopital St Louis, Paris, Not set

Centre Hospitalier Lyon Sud, Pierre Bénite, Not set

CHU de Reims, Reims cedex, Not set

Hematologie - CHU Purpan, Toulouse, Not set

CHRU Hopital Bretonneau, Tours cedex, Not set

CHU Nancy Hematology, Vandoeuvre les Nancy, Not set

Charite, Campus Benjamin Franklin Universitatsmedizin Berlin, Berlin, Not set

Klinikum Chemnitz, Chemnitz, Not set

Universitatsklinikum Carl Gustav Carus, Dresden, Not set

Universitatsklinkikum DusseldorfKlinik fur Hamatologie, Onkologie und klin. Immunoligie, Dusseldorf, Not set

Universitatsklinikum Essen-, Essen, Not set

Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik, Freiburg, Not set

Abt Haematologie - Onkologie / Allg. Krankenhaus Altona, Hamburg, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Universitatsklinikum Jena, Jena, Not set

University of Schleswig Holstein, Kiel, Not set

Klinikum der Universitat zu Koln, Köln, Not set

Universitatsklinikum Leipzig, Leipzig, Not set

Universitatsklinik MuensterMedizinische Klinik A, Muenster, Not set

TU München - Klinikum rechts der Isar, München, Not set

UKT Universitaetsklinikum Tuebingen, Tuebingen, Not set

University Hospital of Ulm, Ulm, Not set

Universitatsklinikum Wurzburg, Würzburg, Not set

University of Athens, Athens, Not set

Cork University HospitalHaematology Consultant, Wilton, Cork

Mater Misericordiae University Hospital, Dublin, Not set

University Hospital Galway, Galway, Not set

Ospedali Riuniti di Ancona, Ancona, Not set

A.O. Policlinico - Università di Bari, Bari, Not set

University of Bologna, Bologna, Not set

Ospedale Ferrarotto, Catania, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Milano, Not set

Universita degli Studi di Padova, Padova, Not set

Casa di Cura La Maddalena, Palermo, Not set

Ospedale Civile di Piacenza, Piacenza, Not set

Azienda Ospedaliero-Universitaria Pisana, Pisa, Not set

Universita degli Studi di Roma La Sapienza - Azienda Policlinico Umberto I, Roma, Not set

Ospedale Sant'Eugenio, Rome, Not set

Azienda Ospedaliera San Giovanni Battista - Ospedale Molinette, Torino, Not set

Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine, Udine, Not set

Ospedale San Bortolo, Vicenza, Not set

VU University Medical Center VU Medisch Centrum, Amsterdam, Not set

Haga Hospital, Den Haag, Not set

Universitair Medisch Centrum Groningen, Groningen, Not set

Erasmus Medical Center, Rotterdam, Not set

University Medical Center Utrecht, Utrecht, Not set

Oslo University Hospital, Rikshospitalet HF, Oslo, Not set

St. Olavs Hospital Trondheim, Trondheim, Not set

Akademia Medyczna w Gdansku Katedra i Klinika Hematologii i Transplantologii, Gdansk, Not set

Szpitala Uniwersyteckiego w. Krakowie, Kraków, Not set

Instytut Hematologii i Transfuzjologii w Warszawie, Warszawa, Not set

Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra, Coimbra, Not set

Instituto Portugues de Oncologia de Lisboa, Lisboa, Not set

Hospital de Santa Maria, Lisboa, Not set

Hospital Geral de Santo António - Serviço de Hematologia Clínica, Porto, Not set

University Hospital Bratislava - Hospital Ss Cyril and Methodius, Bratislava, Not set

Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Universitario de Canarias, La Laguna (Tenerife), Not set

Hospital de La Princesa, Madrid, Not set

Hospital Ramon y Cajal, Madrid, Not set

Hospital Clinico San Carlos, Madrid, Not set

Hospital 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen De La Victoria, Malaga, Not set

Hospital Morales Meseguer, Murcia, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital de Donosti, San Sebastián (Guipuzcoa), Not set

Hospital Clinico Universitario De Santiago De Compostela, Santiago De Compostela, Not set

Hospital Virgen de la Salud, Toledo, Not set

Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Not set

Universitetssjukhuset i Lund, Lund, Not set

Karolinska University HospitalSolna, Stockholm, Not set

Universitatsspital Bern, Bern, Not set

Hopitaux Universitaires de Geneve-HUG, Genèva, Not set

University Hospital Zurich, Zurich, Not set

Ankara University Medical Faculty Cebeci Hospital, Ankara, Not set

Ege University Medical School, Izmir, Not set

Belfast City Hospital Haematology Department, Belfast Northern Ireland, Not set

Kent and Canterbury Hospital, Canterbury/Kent, Not set

Leeds Teaching Hospitals Trust, Leeds, Not set

Royal Liverpool University Hospital, Liverpool, Not set

Christie Hospital NHS Foundation Trust, Manchester, Not set

Newcastle Hospital Foundation Trust, Newcastle upon Tyne, Not set

Royal Marsden Hospital, Sutton (Surrey), Not set

Southmead Hospital, Westbury-on-Trym/ Bristol, Not set

New Cross Hospital, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

NCT04882163

Withdrawn

This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based chemotherapy (Cohort C)) for participants with relapsed or refractory aggressive B-cell lymphoma (R/R a-BCL). All 3 cohorts will be open for enrollment at study start. Part 1 (dose escalation) will be followed by Part 2 (dose expansion), in which participants will be randomized... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/28/2021

Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +26 locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Avera Cancer Institute, Sioux Falls, South Dakota

Medizinische Universität Graz, Graz, Not set

Universitätsklinikum St. Pölten, Sankt Pölten, Not set

Cliniques Universitaires Saint-Luc, Brussels, Not set

Hôpital de Jolimont, La Louvière, Not set

H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Not set

EDOG - Institut Bergonie - PPDS, Bordeaux, Not set

Hôpital François Mitterand, Dijon, Not set

Centre Hospitalier Lyon Sud, Lyon, Not set

EDOG - Institut Claudius Regaud - PPDS, Toulouse, Not set

Gustave Roussy, Villejuif CEDEX, Not set

Samsung Medical Center, Seoul, Not set

Asan Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Hospital Universitario Germans Trias i Pujol, Badalona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Not set

Hospital Universitario Virgen del Rocio - PPDS, Sevilla, Not set

Taipei Veterans General Hospital, Beitou District, Taipei City, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Taiwan University Hospital, Taipei, Zhongzheng Dist., Not set

Beatson West of Scotland Cancer Centre, Glasgow Scotland, Not set

Royal Liverpool University Hospital, Liverpool, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, Not set

Conditions: Lymphoma, B-Cell

Learn More ›

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

NCT00256776

Terminated

This is an international study in adult patients diagnosed with multiple myeloma who have already received at least one autologous stem cell transplantation and who have responded but later progressed, or relapsed, at least one year after transplantation. Eligible patients will be randomly assigned to one of two treatments: either Velcade plus Thalidomide plus Dexamethasone or Thalidomide plus Dexamethasone. Thalidomide and Velcade are two new agents that have recently become available for the... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/21/2021

Locations: Karl-Franzens, Graz, Not set +80 locations

Karl-Franzens, Graz, Not set

Universitatsklinik, Innsbruck, Not set

Medizinische Universitaet Wien, Vienna, Not set

Wilhelminenspital, Vienna, Not set

St Joseph, Arlon, Not set

RHMS, Baudour, Not set

AZ St Jan, Brugge, Not set

Bordet, Brussels, Not set

Erasme CHU, Brussels, Not set

Saint Luc, Brussels, Not set

University Hospital, Brussels, Not set

Saint Joseph, Gilly, Not set

CH Jolimont, Haine-Saint-Paul, Not set

Clinique Saint-Pierre, Ottignies, Not set

UCL Mont-Godinne, Yvoir, Not set

University Hospital, Brno, Not set

Faculty Hospital, Olomouc, Not set

CHU Amiens, Amiens, Not set

CHU Angers, Angers, Not set

Centre Hospitalier d'Antibes, Antibes, Not set

CHU Jean Minjoz, Besancon, Not set

Avicenne, Bobigny, Not set

Polyclinique Bordeaux Nord, Bordeaux, Not set

Morvan CHU, Brest, Not set

Hotel Dieu, Clermont-Ferrand, Not set

ARC CHU Dijon, Dijon, Not set

Hospitalier de Dunkerque, Dunkerque, Not set

Hopital Michallon, Grenoble, Not set

Not set, La Roche sur Yon, Not set

Centre Hospitalier du Havre, Le Havre, Not set

CHRU de Lille, Lille, Not set

Edouard Herriot, Lyon, Not set

Pierre Benite, Lyon, Not set

Not set, Metz, Not set

Centre Hospitalier de Mulhouse, Mulhouse, Not set

CHU Nancy, Nancy, Not set

Hotel Dieu, Nantes, Not set

Archet, Nice, Not set

Hopital Cochin, Paris, Not set

Hotel Dieu, Paris, Not set

Saint Antoine, Paris, Not set

Hopital Jean Bernard, Poitiers, Not set

Robert Debre, Reims, Not set

CHU Hopital Sud, Rennes, Not set

Henri Becquerel, Rouen, Not set

CHRU Tours, Tours, Not set

Klinikum Bremen, Bremen, Not set

University of Cologne, Cologne, Not set

University Hospital, Dresden, Not set

University Hospital, Hamburg, Not set

Medizinische Hochschule, Hannover, Not set

Uniklinik Leipzig, Leipzig, Not set

Universitatsklinikum Schleswig-Hostein, Lubeck, Not set

DKD Wiesbaden, Wiesbaden, Not set

Medizinische und Poliklinik II, Wurzburg, Not set

St Laszlo Hospital, Budapest, Not set

University of Debrecen, Debrecen, Not set

Rambam MC, Haifa, Not set

Sheba MC, Tel Hashomer, Not set

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Not set

Ospedale Riuniti, Bergamo, Not set

AO Spedali Civili di Brescia, Brescia, Not set

Ospedale Maggiore, Catania, Not set

Ospedale Maggiore, Milan, Not set

Federico II, Naples, Not set

V. Cervello, Palermo, Not set

Azienda Ospedale BMM, Reggio di Calabria, Not set

A.O.S. Andrea, Rome, Not set

Kantonsspital Aarau, Aarau, Not set

Kantonsspital Baden, Baden, Not set

Kantonsspital, Basel, Not set

IOSI, Ospedale Civico, Bellinzona, Not set

Inselspital, Bern, Not set

Hopital Cantonal Universitaire, Geneva, Not set

CHUV, Lausanne, Not set

LA Onkologie/Medizin, Thun, Not set

Stadtdpital Triemli, Zurich, Not set

UniversitatsSpital, Zurich, Not set

Heartlands Hospital, Birmingham, Not set

Addenbrookes, Cambridge, Not set

Great Western Hospital, Swindon, Not set

Conditions: Multiple Myeloma

Learn More ›

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

NCT02045017

Completed

The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple myeloma, with moderate or severe renal impairment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/25/2021

Locations: Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Not set +21 locations

Conditions: Multiple Myeloma

Learn More ›

The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery

NCT02767219

Completed

This is a phase III randomised controlled pilot study which aims to assess the effectiveness of the use of bevacizumab in patients who have undergone trabeculectomy surgery, which appear to be showing early signs of failure.

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

08/16/2021

Locations: Moorfields Eye Hospital, Clinical Research Facility, London, Not set

Conditions: Glaucoma

Learn More ›

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

NCT01720875

Completed

Bortezomib is an established treatment in multiple myeloma; it is common practice in the UK to administer bortezomib with dexamethasone. This practice is based on data that supports improved response rates with this combination. Recent trial data indicates that the addition of vorinostat to bortezomib treatment overcomes treatment resistance to bortezomib. As such this current trial is designed to investigate the efficacy, safety and tolerability of combination treatment with vorinostat, bortez... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/09/2021

Locations: Nottingham University Hospital, Nottingham, Nottinghamshire +1 locations

Conditions: Multiple Myeloma

Learn More ›

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

NCT03033511

Terminated

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/28/2021

Locations: Clearview Cancer Institute /ID# 156699, Huntsville, Alabama +307 locations

Clearview Cancer Institute /ID# 156699, Huntsville, Alabama

University of South Alabama /ID# 160975, Mobile, Alabama

Highlands Oncology Group /ID# 156722, Fayetteville, Arkansas

Marin Cancer Care /ID# 159207, Greenbrae, California

Ucsd /Id# 157764, La Jolla, California

LA Hem-Oncology Med Group /ID# 156717, Los Angeles, California

Palo Alto Veterans Institute for Research /ID# 203695, Palo Alto, California

St Jude Hospital dba St Joseph /ID# 156526, Santa Rosa, California

Icri /Id# 157765, Whittier, California

Kaiser Permanente Lone Tree /ID# 159331, Lone Tree, Colorado

Christiana Care Health Service /ID# 159212, Newark, Delaware

Holy Cross Hospital /ID# 156716, Fort Lauderdale, Florida

University of Florida - Archer /ID# 155799, Gainesville, Florida

Memorial Cancer Institute /ID# 156673, Hollywood, Florida

Memorial Cancer Institute /ID# 164052, Hollywood, Florida

Cancer Specialists of North Florida - Southpoint /ID# 156595, Jacksonville, Florida

Georgia Cancer Center /ID# 201894, Atlanta, Georgia

Southeastern Regional Medical /ID# 163064, Newnan, Georgia

St. Luke's Mountain States Tumor Institute - Boise /ID# 156691, Boise, Idaho

NorthShore University HealthSystem - Evanston Hospital /ID# 156664, Evanston, Illinois

Ingalls Memorial Hosp /ID# 156685, Harvey, Illinois

Goshen Center for Cancer Care /ID# 156682, Goshen, Indiana

Ashland-Bellefonte Cancer Ctr /ID# 202901, Ashland, Kentucky

University of Louisville /ID# 156683, Louisville, Kentucky

Ochsner Clinic Foundation /ID# 159136, Baton Rouge, Louisiana

Henry Ford Health System /ID# 156712, Detroit, Michigan

Sparrow Regional Cancer Center, Sparrow Health System /ID# 156590, Lansing, Michigan

Mayo Clinic - Rochester /ID# 160181, Rochester, Minnesota

MidAmerica Division, Inc. /ID# 163530, Kansas City, Missouri

Billings Clinic /ID# 201788, Billings, Montana

Nebraska Hematology Oncology /ID# 156534, Lincoln, Nebraska

MD Anderson Cancer Center at Cooper - Camden /ID# 156681, Camden, New Jersey

Montefiore Medical Center /ID# 201845, Bronx, New York

Northwell Health - Monter Cancer Center /ID# 159252, Lake Success, New York

Icahn School of Med Mt. Sinai /ID# 159210, New York, New York

Stony Brook University Hospital /ID# 159272, Stony Brook, New York

Duke University Medical Center /ID# 156706, Durham, North Carolina

Cone Health /ID# 156689, Greensboro, North Carolina

Cone Health /ID# 163612, Greensboro, North Carolina

Eastern Carolina University /ID# 159264, Greenville, North Carolina

Gabrail Cancer Center Research /ID# 156667, Canton, Ohio

Kaiser Permanente, NW /ID# 201793, Portland, Oregon

Thomas Jefferson University /ID# 156719, Philadelphia, Pennsylvania

VA Pittsburgh HealthcareSystem /ID# 159284, Pittsburgh, Pennsylvania

Rhode Island Hospital /ID# 160834, Providence, Rhode Island

Sarah Cannon Research Institute-Chattanooga /ID# 202933, Chattanooga, Tennessee

Thompson Cancer Survival Ctr /ID# 202460, Knoxville, Tennessee

Tennessee Oncology-Nashville Centennial /ID# 161168, Nashville, Tennessee

Univ Medical Ctr Brackenridge /ID# 155798, Austin, Texas

Parkland Health and Hosp Syste /ID# 170933, Dallas, Texas

UT Southwestern Medical Center /ID# 157848, Dallas, Texas

Houston Methodist Hospital - Scurlock Tower /ID# 202323, Houston, Texas

Medical Oncology Associates /ID# 156715, Spokane, Washington

West Virginia Univ School Med /ID# 156687, Morgantown, West Virginia

Coffs Harbour Hospital /ID# 158880, Coffs Harbour, New South Wales

Gosford Hospital /ID# 158884, Gosford, New South Wales

Newcastle Private Hospital /ID# 203506, Lambton Heights, New South Wales

Royal North Shore Hospital /ID# 158881, Saint Leonards, New South Wales

Calvary North Adelaide Hospita /ID# 161701, Adelaide, South Australia

Sunshine Hospital /ID# 161700, St Albans, Victoria

Affinity Clinical Research Ser /ID# 158887, Nedlands, Not set

SMZ Baumgartner Höhe, Otto-Wagner-Spital und Pflegezentrum /ID# 201776, Vienna, Wien

Krankenhaus Nord - Klinik Floridsdorf /ID# 201768, Vienna, Wien

LKH-Univ. Klinikum Graz /ID# 159563, Graz, Not set

Ordensklinikum Linz GmbH, Elisabethinen /ID# 159564, Linz, Not set

Salzburger Landeskliniken (SALK) /ID# 201779, Salzburg, Not set

Bobruysk Interdistrict Onco. /ID# 169393, Bobruisk, Not set

State Institution Republican Scientific Practical Center of Oncology and Medica /ID# 159383, Lesnoy, Not set

Mogilev Reg Clin Oncology Dis /ID# 159384, Mogilev, Not set

CHU Saint-Pierre /ID# 159009, Bruxelles, Bruxelles-Capitale

Grand Hôpital de Charleroi /ID# 159006, Charleroi, Hainaut

ZNA Middelheim /ID# 159007, Antwerp, Not set

Hopital de Jolimont /ID# 159005, Haine Saint Paul, Not set

CHU Charleroi (Vesale) /ID# 159008, Montigny-le-tilleul, Not set

Hospital Evangelico de Cachoei /ID# 159657, Cachoeiro de Itapemirim, Espirito Santo

Liga Norte Rio Grandense Cont. /ID# 159011, Natal, Rio Grande Do Norte

Associação Hospital de Caridade Ijuí - Centro de Tratamento de Cancer - CACON /ID# 159013, Ijuí, Rio Grande Do Sul

Associação Hospital Beneficente São Vicente de Paulo - Hospital São Vicente de P /ID# 159661, Passo Fundo, Rio Grande Do Sul

Hospital Sao Lucas da PUCRS /ID# 159662, Porto Alegre, Rio Grande Do Sul

Fundacao Pio XII - Hospital de Cancer de Barretos /ID# 159012, Barretos, Sao Paulo

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 159659, Sao Jose Do Rio Preto, Sao Paulo

Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 159658, Rio de Janeiro, Not set

UMHAT Tsaritsa Joanna - ISUL /ID# 159638, Sofia, Not set

UMHAT Sv. Ivan Rilski /ID# 159639, Sofia, Not set

British Columbia Cancer Agency /ID# 163721, Surrey, British Columbia

Brampton Civic Hospital /ID# 204425, Brampton, Ontario

R.S. McLaughlin Durham Regional /ID# 170870, Oshawa, Ontario

Princess Margaret /ID# 170868, Toronto, Ontario

Windsor Regional Cancer Centre /ID# 170869, Windsor, Ontario

Iucpq-Ul /Id# 159530, Québec, Quebec

Fujian Provincial Cancer Hospital /ID# 204864, Fuzhou, Fujian

Harbin Medical University Cancer Hospital /Id# 203638, Harbin, Heilongjiang

Hubei Cancer Hospital /ID# 202886, Wuhan, Hubei

Jilin Cancer Hosptial /ID# 204060, Changchun, Jilin

The Affiliated Cancer Hospital of Xinjiang Medical university /ID# 203641, Urumqi, Xinjiang

Yunnan Cancer Hospital /ID# 204911, Kunming, Yunnan

Zhejiang Cancer hospital /ID# 204640, Hangzhou, Zhejiang

Sir Run Run Shaw Hospital /ID# 206802, Jianggan Hangzhou, Zhejiang

Jiangsu Province Hospital /ID# 205183, Nanjing, Not set

4th Military Medical Universit /ID# 203986, Xi'an, Not set

First Affiliated Hospital of Xi'an Jiaotong University /ID# 203733, Xi'an, Not set

Henan Cancer Hospital /ID# 203983, Zhengzhou Henan, Not set

Henan Cancer Hospital /ID# 204636, Zhengzhou Henan, Not set

Klinicki bolnicki centar Sestre milosrdnice /ID# 159090, Zagreb, Grad Zagreb

Klinika za plucne bolesti Jordanovac /ID# 159505, Zagreb, Grad Zagreb

Klinicki bolnicki centar Rijeka /ID# 159504, Rijeka, Primorsko-goranska Zupanija

Thomayerova nemocnice /ID# 159062, Prague, Praha 4

Nemocnice Rudolfa a Stefanie /ID# 159655, Benesov, Not set

Nemocnice Horovice a.s. /ID# 161186, Horovice, Not set

Vitkovicka nemocnice a. s. /ID# 161187, Ostrava, Not set

FN Plzen /ID# 204097, Plzen, Not set

Oblastni Nemocnice Pribram /ID# 159654, Pribram, Not set

Rigshospitalet /ID# 158055, Copenhagen Ø, Hovedstaden

Herlev Hospital /ID# 158053, Herlev, Hovedstaden

Aalborg University Hospital /ID# 203737, Aalborg, Nordjylland

Odense Universitets Hospital /ID# 158054, Odense C, Syddanmark

East Tallinn Central Hospital /ID# 160019, Tallinn, Not set

North Estonian Medical Centre /ID# 159779, Tallinn, Not set

Docrates Cancer Center /ID# 159591, Helsinki, Not set

CHU Hopital Nord /ID# 160543, Marseille, Bouches-du-Rhone

Hopital Haut-Lévêque /ID# 160547, Pessac CEDEX, Gironde

CHU Calmette /ID# 202706, Lille, Hauts-de-France

Institut Curie /ID# 207514, Paris CEDEX 05, Ile-de-France

Centre Leon Berard /ID# 160550, Lyon CEDEX 08, Rhone

Centre Hosp Intercommunal de Creteil /ID# 162686, Creteil, Val-de-Marne

Hopital Tenon /ID# 160541, Paris, Not set

Hospital Pontchaillou /ID# 160544, Rennes, Not set

Nouvel Hopital Civil (NHC) /ID# 204427, Strasbourg, Not set

Hopital Larrey /ID# 204290, Toulouse, Not set

KH Martha-Maria Halle Dolau /ID# 158794, Halle (Saale), Sachsen-Anhalt

Charite Universitatsmedizin Berlin Campus Virchow Klinikum /ID# 158783, Berlin, Not set

Evangelische Lungenklinik Berl /ID# 158935, Berlin, Not set

Asklepios Fachkliniken M. Gaut /ID# 158789, Gauting, Not set

Thoraxklinik Heidelberg gGmbH /ID# 158871, Heidelberg, Not set

Lungenklinik Hemer /ID# 158790, Hemer, Not set

Klinikum Kassel /ID# 158786, Kassel, Not set

Klinik Loewenstein GmbH /ID# 158870, Löwenstein, Not set

Fachkliniken Wangen /ID# 160779, Wangen, Not set

Metropolitan General Hospital /ID# 202422, Cholargos, Attiki

General Hospital of Chest Diseases of Athens SOTIRIA /ID# 159160, Athens, Not set

Metropolitan Hospital /ID# 159157, Athens, Not set

University General Hospital of Heraklion PA.G.N.I /ID# 202409, Heraklion, Not set

University Hospital of Ioannin /ID# 159158, Ioannina, Not set

General Oncological Hospital /ID# 159159, Nea Kifisia, Not set

Euromedica General Clinic /ID# 159156, Thessaloniki, Not set

Queen Elizabeth Hospital /ID# 159565, Kowloon, Not set

Princess Margaret Hospital /ID# 162810, Lai Chi Kok, Not set

Tuen Mun Hospital /ID# 162435, Tuen Mun, Not set

CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 158962, Miskolc, Borsod-Abauj-Zemplen

Orszagos Koranyi Pulmonologiai Intezet /ID# 158953, Budapest XII, Budapest

Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz - Pulmonologia /ID# 202466, Nyiregyhaza, Szabolcs-Szatmar-Bereg

Semmelweis Egyetem /ID# 158955, Budapest, Not set

Csongrad Megyei Mellkasi Beteg /ID# 158952, Deszk, Not set

St. James's Hospital /ID# 159712, Dublin 8, Dublin

Cork University Hospital /ID# 159715, Cork, Not set

St Vincent's University Hosp /ID# 161678, Dublin, Not set

Beaumont Hospital /ID# 159711, Dublin, Not set

University Hospital Limerick /ID# 159714, Limerick, Not set

University Hospital Waterford /ID# 159713, Waterford, Not set

Rabin Medical Center /ID# 159764, Petakh Tikva, Tel-Aviv

Tel Aviv Sourasky Medical Center /ID# 161467, Tel Aviv-Yafo, Tel-Aviv

Soroka University Medical Center /ID# 159762, Be'er Sheva, Not set

Assaf Harofeh Medical Center /ID# 201883, Be'er Ya'akov, Not set

Rambam Health Care Campus /ID# 202336, Haifa, Not set

Hadassah /ID# 159763, Jerusalem, Not set

Meir Medical Center /ID# 159761, Kfar Saba, Not set

Sheba Medical Center /ID# 159760, Ramat Gan, Not set

IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 160898, Meldola, Emilia-Romagna

Policlinico Universitario Campus Bio-Medico /ID# 160874, Rome, Lazio

AUSL 8 Arezzo Ospedale San Don /ID# 160897, Arezzo, Not set

A.O.U. San Luigi Gonzaga /ID# 158916, Orbassano, Not set

Ospedale Santa Maria delle Cro /ID# 158911, Ravenna, Not set

IFO Istituto Nazionale Tumori /ID# 158912, Rome, Not set

Aichi Cancer Center Hospital /ID# 164976, Nagoya-shi, Aichi

National Cancer Center Hospital East /ID# 165721, Kashiwa-shi, Chiba

Kyushu University Hospital /ID# 165722, Fukuoka-shi, Fukuoka

Kurume University Hospital /ID# 164595, Kurume-shi, Fukuoka

Kanazawa University Hospital /ID# 165127, Kanazawa, Ishikawa

Kanagawa Cardiovascular and Respiratory Center /ID# 165015, Yokohama-shi, Kanagawa

Yokohama City University Hospital /ID# 165746, Yokohama-shi, Kanagawa

Japanese Red Cross Okayama Hospital /ID# 165157, Okayama-shi, Okayama

Kansai Medical University Hospital /ID# 165054, Hirakata-shi, Osaka

Kindai University Hospital /ID# 166395, Osaka-sayama-shi, Osaka

Shizuoka Cancer Center /ID# 166272, Sunto-gun, Shizuoka

Tokushima University Hospital /ID# 166105, Tokushima-shi, Tokushima

National Cancer Center Hospital /ID# 166547, Chuo-ku, Tokyo

Showa University Hospital /ID# 165575, Shinagawa-ku, Tokyo

Wakayama Medical University /ID# 165946, Wakayama-shi, Wakayama

Hyogo Cancer Center /ID# 165138, Akashi, Not set

National Hospital Organization Himeji Medical Center /ID# 165899, Himeji, Not set

Matsusaka City Hospital /ID# 166156, Matsusaka-shi MIE, Not set

Osaka City General Hospital /ID# 165714, Osaka, Not set

Hokkaido Cancer Center /ID# 165236, Sapporo, Not set

Sendai Kousei Hospital /ID# 166491, Sendai, Not set

Kanagawa Cancer Center /ID# 165814, Yokohama, Not set

Dong-A University Hospital /ID# 159305, Busan, Busan Gwang Yeogsi

CHA Bundang Medical center CHA University /ID# 161281, Seongnam si, Gyeonggido

Kyungpook National University Chilgok Hospital /ID# 159301, Daegu, Seoul Teugbyeolsi

Samsung Medical Center /ID# 159304, Seoul, Seoul Teugbyeolsi

Korea University Guro Hospital /ID# 159302, Seoul, Seoul Teugbyeolsi

Chungbuk National University /ID# 159300, Cheongju-si, Not set

Severance Hospital /ID# 159297, Seoul, Not set

Asan Medical Center /ID# 159299, Seoul, Not set

Pauls Stradins Clinical /ID# 158715, Riga, Not set

Riga East Clinical University /ID# 158716, Riga, Not set

Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 160016, Kovno, Kaunas

Klaipeda University Hospital /ID# 160018, Klaipeda, Not set

National Cancer Institute /ID# 160017, Vilnius, Not set

Centro de Investigación Clinica Chapultepec /ID# 160965, Morelia, Michoacan

Health Pharma professional Ser /ID# 160734, Ciudad de México, Not set

Meander Medisch Centrum /ID# 159064, Amersfoort, Not set

Rijnstate /ID# 159063, Arnhem, Not set

Amphia Ziekenhuis /ID# 159065, Breda, Not set

Catharina Ziekenhuis /ID# 158082, Eindhoven, Not set

Maastricht Universitair Medisch Centrum /ID# 161669, Maastricht, Not set

Jeroen Bosch Ziekenhuis /ID# 158081, S Hertogenbosch, Not set

Universitair Medisch Centrum Utrecht /ID# 158083, Utrecht, Not set

Akershus universitetssykehus /ID# 201682, Nordbyhagen, Akershus

Drammen Sykehus /ID# 159572, Drammen, Buskerud

Haukeland University Hospital /ID# 159573, Bergen, Hordaland

St. Olavs Hospital HF /ID# 163110, Trondheim, Sor-Trondelag

Radiumhospitalet, OUS /ID# 159574, Oslo, Not set

Stavanger Universitetssykehus /ID# 159575, Stavanger, Not set

Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 159604, Rzeszów, Podkarpackie

Wojewodzki Szpital Specjalisty /ID# 159603, Bytom, Not set

Szpitale Pomorskie Sp. z o.o /ID# 159605, Gdynia, Not set

Centro Hospitalar Lisboa Norte, EPE /ID# 159957, Lisbon, Lisboa

IPO Lisboa FG, EPE /ID# 159949, Lisboa, Not set

Hospital da Luz, SA /ID# 159954, Lisbon, Not set

Unidade Local Saude Matosinhos /ID# 159950, Matosinhos, Not set

Centro Hospitalar do Porto EPE /ID# 203582, Porto, Not set

Hospital CUF Porto /ID# 159955, Porto, Not set

IPO Porto FG, EPE /ID# 159956, Porto, Not set

National Medical Research Cntr /ID# 169885, Moscow, Moskovskaya Oblast

Arkhangelsk clinical oncology /ID# 159367, Arkhangelsk, Not set

Kaluga Regional Clinical Oncol /ID# 160180, Kaluga, Not set

Clinical Onco Dispensary /ID# 159365, Omsk, Not set

PMI Euromedservice /ID# 159369, Pushkin, Not set

LLC Novaya Clinica /ID# 205523, Pyatigorsk, Not set

OOO Centre of Palliative Medicine De Vita /ID# 206855, Saint Petersburg, Not set

Ogarev Mordovia State Univ /ID# 205742, Saransk, Not set

Smolensk Regional Onc Clin Dis /ID# 159372, Smolensk, Not set

LLC BioEq Ltd. /ID# 159368, St. Petersburg, Not set

N.N. Petrov Research Inst Onc /ID# 159370, St. Petersburg, Not set

Clinical Center Serbia /ID# 160902, Belgrade, Beograd

Clin Hosp Ctr Bezanijska Kosa /ID# 160903, Belgrade, Beograd

Clinical Center of Nis /ID# 160905, NIS, Nisavski Okrug

Institut za onkologiju i radio /ID# 160904, Belgrade, Not set

Institute For Pulmonary Diseas /ID# 164250, Sremska Kamenica, Not set

Cancercare Langenhoven Drive Oncology Centre /ID# 159126, Port Elizabeth, Eastern Cape

Dr Albert, Bouwer and Jordaan Incorporated /ID# 158873, Pretoria, Gauteng

Mary Potter Oncology Centre /ID# 158877, Pretoria, Gauteng

The Oncology Centre /ID# 158872, Durban, Kwazulu-Natal

Cape Town Oncology Trials /ID# 201311, Cape Town, Western Cape

Cancercare Outeniqua Oncology Unit /ID# 200689, George, Western Cape

Hospital Teresa Herrera - CHUAC /ID# 164368, A Coruña, A Coruna

Hospital Regional de Malaga /ID# 164371, Málaga, Malaga

Hospital Parc de Salut del Mar /ID# 159690, Barcelona, Not set

Hospital Universitario Vall d'Hebron /ID# 159708, Barcelona, Not set

Hospital Clinico Universitario San Carlos /ID# 159706, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz /ID# 159693, Madrid, Not set

Hospital Universitario La Paz /ID# 159692, Madrid, Not set

Hospital Clinico Universitario Lozano Blesa /ID# 159709, Zaragoza, Not set

Centralsjukhuset, Karlstad /ID# 163451, Karlstad, Varmlands Lan

Sahlgrenska US Gbg /ID# 159524, Göteborg, Vastra Gotalands Lan

University Hospital Linkoping /ID# 159046, Linkoping, Not set

Karolinska Univ Sjukhuset /ID# 159649, Solna, Not set

Uppsala University Hospital /ID# 159052, Uppsala, Not set

Hopitaux Universitaires de Geneve /ID# 160603, Genève, Geneve

Kantonsspital St. Gallen /ID# 160604, St. Gallen, Sankt Gallen

Universitaetsspital Basel /ID# 160605, Basel, Not set

Luzerner Kantonsspital /ID# 160607, Luzern, Not set

Kantonsspital Winterthur /ID# 161379, Winterthur, Not set

China Medical University Hosp /ID# 158981, Taichung City, Taichung

National Cheng Kung University Hospital /ID# 158799, Tainan City, Tainan

National Taiwan Univ Hosp /ID# 159049, Taipei City, Taipei

Tri-Service General Hospital /ID# 158980, Taipei City, Taipei

Dalin Tzu Chi General Hospital /ID# 158983, Dalin Township, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 158798, Kaohsiung, Not set

Taichung Veterans General Hosp /ID# 159047, Taichung City, Not set

Taipei Veterans General Hosp /ID# 203699, Taipei City, Not set

Hacettepe University Medical Faculty /ID# 159242, Altindağ, Ankara

Erciyes University Medical Fac /ID# 202269, Melikgazi, Kayseri

Ataturk Gogus Hastalikl /ID# 159556, Ankara, Not set

Akdeniz Universitesi Tip Fakul /ID# 160791, Antalya, Not set

Bezmi alem Vakif Universitesi /ID# 202267, Istanbul, Not set

Istanbul Medeniyet Universites /ID# 200126, Istanbul, Not set

Ege University Medical Faculty /ID# 159243, Izmir, Not set

Dr. Suat Seren Gogus Has /ID# 159244, Izmir, Not set

Inonu University /ID# 159245, Malatya, Not set

CI Zaporizhzhia Regional Clinical Oncological Dispensary /ID# 159131, Zaporizhzhia, Zaporizka Oblast

Regional Municipal Non-Profit Enterprise Bukovynian Clinical Oncology Center /ID# 159864, Chernivtsi, Not set

Municipal institution Multifie /ID# 159130, Dnipro, Not set

Regional Center of Oncology /ID# 159132, Kharkiv, Not set

PE PMC Acinus, Medical and Diagnostic Center /ID# 165543, Kropyvnytskyi, Not set

Volyn Regional Medical Oncology Centre /ID# 159133, Lutsk, Not set

Communal Nonprofit Enterprise "Central City Clinical Hospital" of Uzhhorod City /ID# 159865, Uzhhorod, Not set

Cheltenham General Hospital /ID# 169096, Cheltenham, Gloucestershire

Queen Elizabeth Medical Centre /ID# 162899, Birmingham, Not set

The Royal Bournemouth Hospital /ID# 159039, Bournemouth, Not set

Colchester General Hospital /ID# 159042, Colchester, Not set

Hereford County Hospital /ID# 159038, Hereford, Not set

St. George's Healthcare NHS /ID# 202416, London, Not set

Charing Cross Hospital /ID# 161399, London, Not set

Maidstone Hospital /ID# 159043, Maidstone, Not set

Christie NHS Foundation Trust /ID# 159037, Manchester, Not set

The Newcastle Upon Tyne Hospitals NHS Foundation Trust Freeman Hospital /ID# 159044, Newcastle Upon Tyne, Not set

Torbay Hospital - So Devon HC /ID# 159041, Torquay, Not set

Conditions: Small Cell Lung Cancer

Learn More ›

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT03720041

Unknown

Trial Title: FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma Overview: A phase III, multi-centre, randomised controlled trial to compare standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with the novel triplet ixazomib, lenalidomide and dexamethasone (IRD), and to compare maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I) in patients with newly diagnosed multiple myeloma not suitable for a stem cell transplant. All participants receive induction treatment with ixazomib, lenalidomide and dexamethasone and are randomised on a 1:1 basis at trial entry to the use of frailty score-adjusted up-front dose reductions vs. standard up-front dosing followed by toxicity dependent reactive dose-modifications during therapy. Following 12 cycles of induction treatment participants alive and progression-free undergo a second randomisation on a 1:1 basis to maintenance treatment with lenalidomide plus placebo versus lenalidomide plus ixazomib. Participants and their treating physicians will be blinded to maintenance allocation. Participant population: * Newly diagnosed as having Multiple Myeloma (MM) according to the updated IMWG diagnostic criteria 2014 (see Appendix 1 for criteria) * Not eligible for stem cell transplant * Aged at least 18 years * Able to provide written informed consent Number of participants: 740 participants will be entered into the trial at Randomisation 1 (R1), with 478 participants at Randomisation 2 (R2). Objectives: The primary objectives of this study are to determine: * Early treatment cessation (within 60 days of randomisation) for standard versus frailty-adjusted up-front dosing * Progression-free survival (PFS, from maintenance randomisation) for lenalidomide + placebo (R) versus lenalidomide + ixazomib (R+I) The secondary objectives of this study are to assess progression-free survival (PFS) for standard versus frailty-adjusted up-front dosing reductions, time to progression, time to 2nd PFS event (PFS2), overall survival (OS), survival after progression, deaths within 12 months of R1, overall response rate (ORR), attainment of ≥VGPR, attainment of MRD negativity, duration of response, time to improved response, time to next treatment, treatment compliance and total amount of therapy delivered, toxicity \& safety including the incidence of SPMs, Quality of Life (QoL), cost effectiveness of standard versus frailty-adjusted up-front dosing of IRD and cost-effectiveness of R + I versus R. Exploratory objectives are prospective validation of a novel frailty risk score (UK-MRA Myeloma Risk Profile - MRP), usefulness of Karnofsky Performance Status (PS), and association of molecular subgroups with response, PFS and OS. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/10/2021

Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +109 locations

Aberdeen Royal Infirmary, Aberdeen, Not set

Nevill Hall Hospital, Abergavenny, Not set

Wrightington Hosptial, Appley Bridge, Not set

Ysbyty Gwynedd, Bangor, Not set

North Devon District Hospital, Barnstaple, Not set

Furness General Hospital, Barrow In Furness, Not set

Basingstoke and North Hampshire Hospital, Basingstoke, Not set

Royal United Hospital, Bath, Not set

Belfast City Hospital, Belfast, Not set

Birmingham Heartlands Hospital, Birmingham, Not set

Queen Elizabeth Hospital, Birmingham, Not set

Royal Blackburn Hospital, Blackburn, Not set

Blackpool Victoria Hospital, Blackpool, Not set

Royal Bolton Hospital, Bolton, Not set

Pilgrim Hospital, Boston, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Bradford Royal Infirmary, Bradford, Not set

Bristol Haematology and Oncology Centre, Bristol, Not set

Southmead Hospital, Bristol, Not set

Queen's Hospital, Burton Upon Trent, Not set

Kent and Canterbury Hospital, Canterbury, Not set

Chelmsford & Essex Hospital, Chelmsford, Not set

Cheltenham General Hospital, Cheltenham, Not set

Countess of Chester Hospital, Chester, Not set

St Richard's Hospital, Chichester, Not set

Colchester General Hospital, Colchester, Not set

University Hospital Coventry, Coventry, Not set

Croydon University Hospital, Croydon, Not set

Royal Derby Hospital, Derby, Not set

Dorset County Hospital, Dorchester, Not set

Russells Hall Hospital, Dudley, Not set

Ninewells Hospital, Dundee, Not set

Western General Hospital, Edinburgh, Not set

Royal Devon & Exeter Hospital, Exeter, Not set

Medway Maritime Hospital, Gillingham, Not set

Gloucestershire Royal Hospital, Gloucester, Not set

Grantham and District Hospital, Grantham, Not set

Diana Princess of Wales Hospital, Grimsby, Not set

Royal Surrey County Hospital, Guildford, Not set

Calderdale Royal Hospital, Halifax, Not set

Harrogate District Hospital, Harrogate, Not set

Withybush General Hospital, Haverfordwest, Not set

Hereford County Hospital, Hereford, Not set

Huddersfield Royal Infirmary, Huddersfield, Not set

Castle Hill Hospital, Hull, Not set

Raigmore Hospital, Inverness, Not set

Ipswich Hospital, Ipswich, Not set

Airedale Hospital, Keighley, Not set

Westmorland General Hospital, Kendal, Not set

Kettering General Hospital, Kettering, Not set

Kidderminster Hospital & Treatment Centre, Kidderminster, Not set

Victoria Hospital, Kirkcaldy, Not set

Royal Lancaster Infirmary, Lancaster, Not set

St James's University Hospital, Leeds, Not set

Leicester Royal Infirmary, Leicester, Not set

Lincoln County Hospital, Lincoln, Not set

Aintree University Hospital, Liverpool, Not set

Royal Liverpool Hospital, Liverpool, Not set

Guy's Hospital, London, Not set

King's College Hospital, London, Not set

Queen Elizabeth Hospital Greenwich, London, Not set

St Bartholomew's Hospital, London, Not set

University College Hospital, London, Not set

University Hospital Lewisham, London, Not set

Maidstone Hospital, Maidstone, Not set

Manchester Royal Infirmary, Manchester, Not set

James Cook University Hospital, Middlesbrough, Not set

Freeman Hospital, Newcastle, Not set

Royal Gwent Hospital, Newport, Not set

North Tyneside General Hospital, North Shields, Not set

Nottingham City Hospital, Nottingham, Not set

Royal Oldham Hospital, Oldham, Not set

Princess Royal University Hospital, Orpington, Not set

Peterborough City Hospital, Peterborough, Not set

Derriford Hospital, Plymouth, Not set

Whiston Hospital, Prescot, Not set

Royal Preston Hospital, Preston, Not set

Royal Berkshire Hospital, Reading, Not set

Alexandra Hospital, Redditch, Not set

Glan Clwyd Hospital, Rhyl, Not set

Queen's Hospital, Romford, Not set

Salford Royal Hospital, Salford, Not set

Salisbury District Hospital, Salisbury, Not set

Scarborough General Hospital, Scarborough, Not set

Scunthorpe General Hospital, Scunthorpe, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Royal Shrewsbury Hospital, Shrewsbury, Not set

Southampton General Hospital, Southampton, Not set

St Helens Hospital, St Helens, Not set

Stafford County Hospital, Stafford, Not set

Stepping Hill Hospital, Stockport, Not set

Royal Stoke University Hospital, Stoke-on-Trent, Not set

Sunderland Royal Hospital, Sunderland, Not set

Good Hope Hospital, Sutton Coldfield, Not set

Singleton Hospital, Swansea, Not set

St George's Hospital, Tooting, Not set

Torbay District General Hospital, Torquay, Not set

Royal Cornwall Hospital, Truro, Not set

Tunbridge Wells Hospital, Tunbridge Wells, Not set

Hillingdon Hospital, Uxbridge, Not set

Pinderfields General Hospital, Wakefield, Not set

Warwick Hospital, Warwick, Not set

Sandwell General Hospital, West Bromwich, Not set

Royal Albert Edward Infirmary, Wigan, Not set

Royal Hampshire County Hospital, Winchester, Not set

New Cross Hospital, Wolverhampton, Not set

Worcestershire Royal Hospital, Worcester, Not set

Worthing Hospital, Worthing, Not set

Wrexham Maelor Hospital, Wrexham, Not set

York Hospital, York, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

NCT03567616

Terminated

This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM) who received at least 1 prior line of therapy with documented evidence of progression during or after the participant's last treatment regimen. The study was designed to consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the participant... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/09/2021

Locations: John B. Amos Cancer Center - C /ID# 202055, Columbus, Georgia +10 locations

Conditions: Multiple Myeloma

Learn More ›